Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes.

OncoTargets and therapy·2016

Same author

Similar Outcomes of Standard Radiotherapy and Hypofractionated Radiotherapy Following Breast-Conserving Surgery.

Medical science monitor : international medical journal of experimental and clinical research·2015

Same author

[Protein expression of p53, bcl-2, and bax in adenoid cystic carcinoma of lacrimal gland].

Zhonghua yi xue za zhi·2008

Same author

Enzymic thin film coatings for bioactive materials.

Biotechnology progress·2008

Same author

Orexigenic hormone ghrelin attenuates local and remote organ injury after intestinal ischemia-reperfusion.

PloS one·2008

Same author

[Application of carboxylated polystyrene latex particles in the detection of aflatoxin B1].

Wei sheng yan jiu = Journal of hygiene research·2008

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Brain metastasis treated with Cyberknife.

Zhi-zhen Wang¹, Zhi-yong Yuan, Wen-cheng Zhang

¹Key Laboratory of Cancer Prevention and Therapy and Department of Radiation Therapy, Tianjin Cancer Hospital of Tianjin Medical University, Tianjin, China.

Chinese Medical Journal

|September 29, 2009

Summary

CyberKnife stereotactic radiosurgery effectively treats brain metastases with high fractional doses, achieving excellent clinical outcomes and survival rates. This method offers a valid and appropriate treatment shortcut for patients with brain metastasis.

More Related Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Jun 20, 2026

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Area of Science:

Neurosurgery
Radiation Oncology
Medical Physics

Background:

CyberKnife enables higher fractional doses in stereotactic radiosurgery, enhancing clinical efficacy.
Brain metastases represent a significant challenge in cancer treatment, necessitating advanced therapeutic strategies.

Purpose of the Study:

To retrospectively analyze the clinical outcomes of brain metastases treated with CyberKnife.
To evaluate the efficacy and safety of CyberKnife in managing brain metastases.

Main Methods:

Retrospective analysis of 40 patients with 68 brain metastases treated with CyberKnife.
Dosage: 18-36 Gy total dose (5-25 Gy/F, 1-5 F).
Evaluation of clinical symptom remission, new foci, local control, and survival rates over 14 months.

Main Results:

90.0% clinical remission within 1 week; 77.9% local control at 3 months.
3-month, 6-month, and 1-year survival rates were 97.5%, 82.5%, and 67.5%, respectively.
No correlation found between new lesions and patient/treatment factors.

Conclusions:

CyberKnife achieves excellent clinical outcomes with higher fractional doses.
It is a valid and appropriate treatment option for brain metastases.